Tigermed

We’re pleased to present part two of our interview series with Dr. Seigo Kinuya. Interview with Scientific Advisor Dr. Seigo Kinuya: "Paving the Way for the Future of Theranostics in Japan" In this part, we asked Dr. Kinuya about the essential steps needed to expand nuclear medicine therapy in Japan and the hopeful future he wishes to share with patients. We hope you enjoy reading and find it inspiring! #ExpertInterviewSeries, #Theranostics,#Micron,#Imaging,#ImagingCRO,#clinicalresearch, #clinicalstudies, #clinicaltrials,#CRO, #ACROSSGlobal,#medicalimaging,#centralimaging,#imagingforclinicaltrials

Advancing Medical Device Innovation through Clinical Excellence — Tigermed EMEA’s Expertise In today’s fast-evolving healthcare landscape, medical devices and in-vitro diagnostics (IVD) play a crucial role in improving patient care, diagnosis, and treatment precision. Behind every approved and reliable device lies a rigorous clinical journey — and Tigermed EMEA is proud to be part of that process. Proven Expertise in Medical Device & IVD Studies As part of the Tigermed Group, our team has contributed to the design, management, and monitoring of hundreds of clinical trials for medical devices and diagnostic technologies worldwide. According to the group’s public reports, Tigermed has supported over 900 Medical Device and IVD projects, collaborating with more than 1,900 manufacturers across 30+ countries. From early feasibility to pivotal trials, Tigermed EMEA ensures every step meets the highest regulatory and ethical standards — helping sponsors navigate the complex path from innovation to market approval. Examples of Our Work In international clinical trial databases such as ClinicalTrials.gov, several studies list Tigermed and its European affiliate Opera CRO (a Tigermed Group Company) as collaborators for investigational medical devices, including: Polybactum– a clinical investigation for a gynecological medical device. Jalucomplex – a series of studies evaluating dermal fillers and aesthetic medical devices. Multiple trials across Europe assessing the safety, performance, and biocompatibility of novel medical technologies. These projects demonstrate our extensive experience in supporting regulatory submissions, clinical monitoring, data management, and medical writing for device studies — always focusing on patient safety and data integrity. Why It Matters Each device study contributes not only to scientific evidence but also to patient well-being and healthcare advancement. Through strategic partnerships and dedicated operational excellence, Tigermed EMEA enables innovators to bring safer, more effective technologies to patients faster. Looking Ahead As the regulatory environment evolves under MDR and IVDR in Europe, Tigermed EMEA remains committed to guiding sponsors through every step — from clinical development to successful market access. Our mission is clear: to accelerate medical innovation with quality, compliance, and care. 🔗 #TigermedEMEA #ClinicalResearch #MedicalDevices #IVD #CRO #Innovation #PatientSafety #ClinicalExcellence

Thank you, CPHI Frankfurt! 25km walked, countless conversations, and meaningful connections made. Always a great opportunity to meet our colleagues from Tigermed, re-connect with our partners, and attend insightful lectures. To everyone who took the time to connect with us—we appreciate you. Let's continue the conversation at bd@martifarm.com. #CPHI #CPHIFrankfurt #Pharma #Networking

Celebrating 30 Years of Excellence – From Opera CRO to Tigermed EMEA This year we proudly celebrate 30 years of commitment, growth, and innovation in clinical research. Founded three decades ago, Opera CRO has built a strong reputation for quality, reliability, and scientific excellence. Over the years, our passionate teams have contributed to the success of countless clinical studies, supporting the development of life-changing therapies for patients around the world.   Five years ago, Opera CRO began a new and exciting chapter by joining the Tigermed Group family — a partnership that has strengthened our global reach, integrated our expertise, and expanded the opportunities to deliver even greater value to our clients and partners. Today, as part of Tigermed Group, we continue to advance our shared mission: to improve human health through excellence in delivery, innovation, and collaboration. We thank all our colleagues, partners, and clients who have been part of this incredible journey. Together, we look forward to the next decades of advancing science and health — with the same passion and dedication that defined our first 30 years. Tigermed #Tigermed #OperaCRO #ClinicalResearch #30YearsOfExcellence #Anniversary #Teamwork #Innovation #LifeSciences